Suppr超能文献

麻疹-腮腺炎-风疹疫苗接种对预防来自国外旅行的美国家庭儿科旅行者输入性麻疹的临床和经济影响。

The Clinical and Economic Impact of Measles-Mumps-Rubella Vaccinations to Prevent Measles Importations From US Pediatric Travelers Returning From Abroad.

机构信息

Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

出版信息

J Pediatric Infect Dis Soc. 2022 Jun 22;11(6):257-266. doi: 10.1093/jpids/piac011.

Abstract

BACKGROUND

Pediatric international travelers account for nearly half of measles importations in the United States. Over one third of pediatric international travelers depart the United States without the recommended measles-mumps-rubella (MMR) vaccinations: 2 doses for travelers ≥12 months and 1 dose for travelers 6 to <12 months.

METHODS

We developed a model to compare 2 strategies among a simulated cohort of international travelers (6 months to <6 years): (1) No pretravel health encounter (PHE): travelers depart with baseline MMR vaccination status; (2) PHE: MMR-eligible travelers are offered vaccination. All pediatric travelers experience a destination-specific risk of measles exposure (mean, 30 exposures/million travelers). If exposed to measles, travelers' age and MMR vaccination status determine the risk of infection (range, 3%-90%). We included costs of medical care, contact tracing, and lost wages from the societal perspective. We varied inputs in sensitivity analyses. Model outcomes included projected measles cases, costs, and incremental cost-effectiveness ratios ($/quality-adjusted life year [QALY], cost-effectiveness threshold ≤$100 000/QALY).

RESULTS

Compared with no PHE, PHE would avert 57 measles cases at $9.2 million/QALY among infant travelers and 7 measles cases at $15.0 million/QALY among preschool-aged travelers. Clinical benefits of PHE would be greatest for infants but cost-effective only for travelers to destinations with higher risk for measles exposure (ie, ≥160 exposures/million travelers) or if more US-acquired cases resulted from an infected traveler, such as in communities with limited MMR coverage.

CONCLUSIONS

Pretravel MMR vaccination provides the greatest clinical benefit for infant travelers and can be cost-effective before travel to destinations with high risk for measles exposure or from communities with low MMR vaccination coverage.

摘要

背景

在美国,小儿国际旅行者占麻疹输入病例的近一半。超过三分之一的小儿国际旅行者离开美国时未接种推荐的麻疹-腮腺炎-风疹(MMR)疫苗:12 个月及以上旅行者接种 2 剂,6 至<12 个月旅行者接种 1 剂。

方法

我们为一组模拟国际旅行者(6 个月至<6 岁)建立了一个模型,比较了两种策略:(1)无旅行前健康接触(PHE):旅行者离开时的基线 MMR 疫苗接种状况;(2)PHE:符合 MMR 条件的旅行者提供疫苗接种。所有小儿旅行者都面临特定目的地麻疹暴露风险(平均每百万旅行者 30 例暴露)。如果暴露于麻疹,旅行者的年龄和 MMR 疫苗接种状况决定感染风险(范围为 3%-90%)。我们从社会角度考虑了医疗费用、接触者追踪和旷工损失。我们在敏感性分析中改变了输入参数。模型结果包括预期的麻疹病例、成本和增量成本效益比(每质量调整生命年的美元数 [$/质量调整生命年(QALY)],成本效益阈值≤100000 美元/QALY)。

结果

与无 PHE 相比,PHE 可使婴儿旅行者每百万旅行者中避免 57 例麻疹病例,每百万旅行者中节省 920 万美元/QALY;学龄前旅行者每百万旅行者中避免 7 例麻疹病例,每百万旅行者中节省 1500 万美元/QALY。PHE 的临床效益对婴儿最大,但仅对前往麻疹暴露风险较高的目的地(即≥160 例/百万旅行者)或如果更多的美国获得的病例是由受感染者引起的旅行者(如 MMR 覆盖率有限的社区)旅行时具有成本效益。

结论

旅行前 MMR 疫苗接种可为婴儿旅行者提供最大的临床效益,并且可以在前往麻疹暴露风险较高的目的地或 MMR 疫苗接种覆盖率较低的社区之前具有成本效益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00ea/9214784/b25d1e234f6d/piac011_fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验